Understanding the Role of Proton Therapy for Meningioma

Meningiomas represent the most common primary intracranial neoplasms in adult neuro-oncology practice. Although neurosurgical resection remains the primary standard of care, achieving complete surgical clearance is often impossible. Specifically, tumors involving the skull base, cavernous sinus, or posterior fossa frequently lie close to vital neurovascular structures. In these complex scenarios, incomplete resection necessitates effective adjuvant radiotherapy to prevent recurrence. Recently, proton therapy for meningioma has gained prominence as an advanced charged particle modality. The unique physical characteristics of protons allow targeted radiation delivery with minimal exit dose. Consequently, adjacent normal brain parenchyma receives substantially lower radiation exposure compared to conventional photon therapy. To clarify clinical efficacy and safety across diverse tumor grades, a systematic review and meta-analysis synthesized data from nineteen published cohorts comprising 1,431 adult patients. The investigation evaluated critical endpoints, including five-year overall survival, radiologic local control, and treatment complications. Ultimately, this pooled analysis provides crucial clinical evidence for neurosurgeons and radiation oncologists designing treatment protocols for anatomically challenging lesions.

Dosimetric Principles and Advantages Over Photon Modalities

Traditional photon-based irradiation techniques deposit energy continuously along their physical path. Consequently, healthy tissues situated before and behind the intracranial target inevitably receive unwanted radiation doses. In marked contrast, proton beams exhibit the distinctive Bragg peak phenomenon. Protons enter the body with a relatively low entrance dose, deposit maximum therapeutic ionizing energy at a specified penetration depth, and stop abruptly. As a result, no exit dose reaches tissues beyond the tumor margin. Radiation oncologists leverage this characteristic to construct exceptionally conformal treatment volumes around irregularly shaped skull-base tumors. Furthermore, sparing nearby critical neurovascular structures remains a major clinical benefit. Protons significantly reduce unnecessary dose delivery to the optic chiasm, brainstem, cochlea, and hippocampi. Similarly, minimizing the overall integral radiation dose lowers the long-term danger of radiation-induced secondary malignancies. Clinical studies also indicate that sparing healthy brain parenchyma preserves neurocognitive performance and endocrine stability over extended periods. Therefore, particle therapy offers an outstanding dosimetric alternative whenever target volumes abut vulnerable eloquent regions.

Tumor Grade Distribution and Treatment Dosages

The systematic review captured a broad spectrum of meningioma grades across diverse clinical cohorts. Specifically, World Health Organization Grade I tumors formed the predominant group, representing 70.6% of the 1,431 patients. In addition, atypical Grade II tumors comprised 25.2% of the cases, whereas malignant Grade III lesions constituted 4.2%. This distribution matches real-world surgical neuro-oncology patterns, where benign histology dominates but aggressive variants require intensified therapy. Furthermore, the radiation regimens examined across the nineteen studies demonstrated wide variability based on histology and surgical margins. Delivered proton doses ranged from 13 to 70.2 Gy (relative biological effectiveness). Benign lesions generally received lower fractionated doses designed to arrest growth without inducing vascular damage. Conversely, higher-grade tumors required dose-escalated regimens to overcome intrinsic cellular radioresistance and curb local invasion. Importantly, the analyzed cohorts included both passively scattered and active pencil beam scanning modalities. Consequently, the meta-analysis offers a comprehensive overview of modern proton treatment delivery methods across distinct clinical environments.

Long-Term Survival and Radiologic Local Tumor Control

Evaluating disease control outcomes demonstrates the therapeutic effectiveness of proton irradiation. Across nine studies with available survival data, the pooled five-year overall survival proportion was 91% (95% CI 88–94; p < 0.001). This favorable outcome underscores the durable longevity achieved by patients undergoing particle radiation. Furthermore, the pooled radiologic local control rate averaged 71% (95% CI 50–86). Although this indicates substantial tumor stability, researchers observed notable heterogeneity across the included cohorts. Histological tumor grade substantially influenced local control differences. Patients with WHO Grade I meningiomas experienced significantly higher long-term control rates than those harboring Grade II or Grade III tumors. Moreover, definitive proton therapy achieved stable disease containment in patients with surgically unresectable primary tumors. Similarly, adjuvant proton delivery suppressed regrowth in patients with subtotal surgical resections. Therefore, particle therapy establishes durable tumor control while preventing symptom progression, confirming its vital role in definitive and postoperative management paradigms.

Evaluating Safety Profiles and Complication Rates in Practice

Assessing treatment-related morbidity is critical when evaluating any advanced radiation modality. In this systematic review, the pooled complication rate was 16% (95% CI 5–27; p < 0.001). While this pooled rate confirms acceptable safety, significant statistical heterogeneity existed across individual institutions. Fortunately, most documented adverse events were mild to moderate in severity. Typical acute side effects included transient localized alopecia, scalp erythema, and mild fatigue. However, serious late toxicities also emerged in isolated cases, including symptomatic radiation necrosis, hypopituitarism, visual deterioration, and post-treatment seizures. Notably, tumors located within the sphenoid ridge and middle cranial fossa exhibited increased vulnerability to peri-tumoral edema and epileptogenic activity. Consequently, radiation oncologists must prioritize precise target delineation and careful dose constraints for adjacent brain parenchyma. Furthermore, regular postoperative imaging and proactive clinical monitoring allow early detection of radiation injury. Timely intervention with corticosteroids or hyperbaric oxygen can successfully alleviate severe edema when complications arise.

Clinical Implications and Future Directions for Neuro-Oncology

The meta-analysis highlights significant implications for clinical practice and multidisciplinary decision-making. In past decades, neurosurgeons faced difficult choices between radical resection and acceptable functional preservation. Now, the proven effectiveness of proton irradiation supports a balanced approach prioritizing cranial nerve integrity over aggressive gross total resection. Surgeons can deliberately leave residual tumor near critical neurovascular bundles, knowing adjuvant proton therapy achieves reliable tumor control. In addition, proton therapy offers a viable salvage option for recurrent lesions previously exposed to photon radiation. Nevertheless, several knowledge gaps remain within the current literature. Future investigations should conduct prospective randomized controlled trials comparing pencil beam scanning against advanced photon stereotactic techniques. Moreover, researchers must systematically measure patient-reported quality of life, neurocognitive outcomes, and institutional cost-effectiveness. As proton therapy centers become more accessible globally, standardized patient selection criteria will optimize clinical utility. Ultimately, integrating particle radiotherapy into evidence-based treatment pathways will enhance long-term patient outcomes worldwide.

Frequently Asked Questions

What are the primary benefits of proton therapy for meningioma?

Proton therapy provides superior dosimetric precision compared to photon radiation due to the Bragg peak phenomenon. Consequently, protons deposit maximal therapeutic energy directly inside the tumor and deliver minimal exit dose. This steep dose falloff protects adjacent critical structures, preserving cognitive function and lowering late radiation-induced complications.

Which meningioma patients benefit most from proton beam irradiation?

Patients with surgically inaccessible, skull-base, or recurrent meningiomas benefit most from proton therapy. In addition, individuals with tumors encroaching on sensitive neural anatomy, such as the optic apparatus or brainstem, gain significant neuroprotection. The technique is also ideal for younger patients requiring reduced lifetime radiation exposure.

What are the most frequent toxicities associated with proton therapy?

Reported acute toxicities commonly include localized alopecia, fatigue, scalp irritation, and mild headaches. Less frequently, patients may experience late complications such as radiation-induced necrosis, hormonal dysfunction, or peri-tumoral edema. Fortunately, the overall pooled complication rate remains around 16%, and severe permanent adverse events occur rarely in clinical cohorts.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Wijaya JH et al. Effectiveness and safety of proton therapy in intracranial meningioma treatment: a systematic review and meta-analysis. Neurosurg Rev. 2026 May 09. doi: 10.1007/s10143-026-04319-5. PMID: 42104122.


2. Mizumoto M et al. Radiotherapy Strategies for WHO Grade 1 Meningioma: A Systematic Review and Meta-Analysis Comparing Proton Therapy, Conventional Radiotherapy, and Radiosurgery. Cancers (Basel). 2026 Aug 05;18(15):2506. doi: 10.3390/cancers18152506. PMID: 42588721.


3. Goldbrunner R et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncol. 2021 Nov;23(11):1821-1834. doi: 10.1093/neuonc/noab150.